ABSTRACT
ObjectiveTo observe the effect of Momordica charantia extract （MCE） on the gluconeogenesis signaling pathway in diabetes rats. MethodMale Zucker Diabetic Fatty （ZDF） rats aged 5-6 weeks were randomly divided into a model group and an MCE group （administered MCE at a dose of 0.40 g·kg-1 by gavage）. Additionally， seven healthy male ZDF （fa/+） rats were assigned to the normal group and received administration once daily for six consecutive weeks. During the experiment， the general condition of the rats was observed， and body weight was recorded. Fasting blood glucose and random blood glucose levels were measured in the 1st， 3rd， and 5th weeks. In the 6th week， an oral glucose tolerance test （OGTT） was conducted， and serum levels of triglycerides （TG）， free fatty acid （FFA）， total cholesterol （TC）， aspartate aminotransferase （AST）， and alanine aminotransferase （ALT） were measured. Hematoxylin-eosin （HE） staining was performed to examine liver morphology， periodic acid-Schiff （PAS） staining was used to assess hepatic glycogen storage， and Real-time polymerase chain reaction （PCR） was employed to measure the mRNA expression of phosphoenolpyruvate carboxykinase （PEPCK） and glucose-6-phosphatase （G6Pase） in the liver. Western blot analysis was conducted to measure the phosphorylation level of forkhead box protein O1 （FoxO1） and the protein expression of PEPCK and G6Pase in the liver. ResultCompared with the model group， the MCE group showed significant improvements in body weight， fasting blood glucose， random blood glucose， and glucose tolerance （P<0.05， P<0.01） and reduced serum levels of FFA， TC， and TG （P<0.05， P<0.01）. There were no significant differences in ALT and AST between the two groups. In the MCE group， the HE staining revealed more orderly liver cell arrangement and reduced hepatic steatosis and the PAS staining showed increased hepatic glycogen storage. The protein expression of p-FoxO1 in the liver was significantly elevated （P<0.01）， while there was no significant difference in FoxO1 protein expression. The mRNA and protein expression of PEPCK and G6Pase significantly decreased （P<0.05）. ConclusionMCE exhibits glucose-lowering and lipid-lowering effects， improves glucose tolerance， and enhances hepatic glycogen storage. These effects may be attributed to the upregulation of p-FoxO1， leading to the inhibition of PEPCK and G6Pase expression and the regulation of gluconeogenesis-related processes.
ABSTRACT
A 24-year-old male was admitted due to recurrent redness, swelling, fever and pain in the ankle, frequently accompanied by hungry feeling. Dual energy CT scans showed multiple small gouty stones in the posterior edge of the bilateral calcaneus and in the space between the bilateral metatarsophalangeal joints. The laboratory examination results indicated hyperlipidemia, high lactate lipids, and low fasting blood glucose. Histopathology of liver biopsy showed significant glycogen accumulation. The results of gene sequencing revealed the compound heterozygous mutations of the G6PC gene c.248G>A (p.Arg83His) and c.238T>A (p.Phe80Ile) in the proband. The c.248G>A mutation was from mother and the c.238T>A mutation was from father. The diagnosis of glycogen storage disease type Ⅰa was confirmed. After giving a high starch diet and limiting monosaccharide intake, as well as receiving uric acid and blood lipids lowering therapy, the condition of the patient was gradually stabilized. After a one-year follow-up, there were no acute episodes of gout and a significant improvement in hungry feeling in the patient.
Subject(s)
Male , Humans , Young Adult , Adult , Glycogen Storage Disease Type I/genetics , Gout/genetics , Mutation , LipidsABSTRACT
Objective: To investigate the effects of glucose-6-phosphatase catalytic subunit (G6PC) recombinant adenovirus on proliferation and cell cycle regulation of liver cancer cells. Methods: Recombinant adenovirus AdG6PC was constructed. Huh7 cells and SK-Hep1 cells were set as Mock, AdGFP and AdG6PC group. Cell proliferation and clone formation assay were used to observe the proliferation of liver cancer cells. Transwell and scratch assay were used to observe the invasion and migration of liver cancer cells. Cell cycle flow cytometry assay was used to analyze the effect of G6PC overexpression on the proliferation cycle of liver cancer cells. Western blot was used to detect the effect of G6PC overexpression on the cell-cycle protein expression in liver cancer cells. Results: The recombinant adenovirus AdG6PC was successfully constructed. Huh7 and SK-Hep1 cells proliferation assay showed that the number of proliferating cells in the AdG6PC group was significantly lower than the other two groups (P < 0.05). Clone formation assay showed that the number of clones was significantly lower in AdG6PC than the other two groups (P < 0.05), suggesting that G6PC overexpression could significantly inhibit the proliferation of liver cancer cells. Transwell assay showed that the number of cell migration was significantly lower in AdG6PC than the other two groups (P < 0.05). Scratch repair rate was significantly lower in AdG6PC than the other two groups (P < 0.05), suggesting that G6PC overexpression can significantly inhibit the invasion and migration of liver cancer cells. Cell cycle flow cytometry showed that G6PC overexpression had significantly inhibited the Huh7 cells G(1)/S phase transition. Western blot result showed that G6PC overexpression had down-regulated the proliferation in cell-cycle related proteins expression. Conclusion: G6PC inhibits the proliferation, cell-cycle related expression, and migration of liver cancer cells by inhibiting the G(1)/S phase transition.
Subject(s)
Humans , Catalytic Domain , Cell Cycle Checkpoints , Cell Line, Tumor , Cell Proliferation , Gene Expression Regulation, Neoplastic , Glucose-6-Phosphatase/metabolism , Liver Neoplasms/geneticsABSTRACT
Objective To investigate the diagnostic significance of combined detection of rheumatoid factor (RF),anti-cyclic cit-rullinated antibody (anti-CCP antibody),glucose-6-phosphatase (GPI)and anti-RA33 antibody in rheumatoid arthritis (RA).Meth-ods One hundred and twenty-six patients with RA,60 patients with other autoimmune diseases and 60 healthy subjects undergoing physical examination were selected as the research subjects.The singled detection of RF,anti-CCP antibody,GPI and anti-RA33 an-tibody,and their combined detection were used to analyze their roles in RA diagnosis.Results Compared with the healthy control group,the four indexes in the RA group were increased,the difference was statistically significant (P<0.05),the RF level in the autoimmune diseases group was increased compared with the control group,the difference was statistically significant(P<0.05). Compared with the the autoimmune diseases group,the four indexes in the RA group were increased,the difference was statistically significant (P<0.05).The sensitivity and specificity of RF to RA were 77.77% and 63.33%;the sensitivity and specificity of anti-CCP antibody to RA were 69.04% and 95.00%;the sensitivity and specificity of GPI antibody to RA were 25.40% and 100.00%;the sensitivity and specificity of anti-RA33 antibody were 27.77% and 99.16%,respectively.The specificity of combined 2 indica-tors was increased from 63.33% to 85.00%,which of combined 3 indicators was increased to 93.33% and which of combined 4 in-dicators even reached to 100.00%.Conclusion The combination of RF,anti-CCP antibody,GPI and anti-RA33 antibody indicators greatly increases with the sensitivity and specificity for diagnosing RA and has clinical significance.
ABSTRACT
Objective To examine the effects of Sapium ellipticum (SE) leaf extract on the hepatic activities of glucokinase and glucose-6-phosphatase in streptozotocin-induced diabetic Wistar rats. Methods STZ-induced diabetic Wistar rats (four groups, n = 8) were used in this study. SE was assessed at two different doses, 400 and 800 mg/kg BW, in comparison with metformin (METF) (12 mg/kg BW) as a reference antidiabetic drug. All treatments were done orally (p.o), twice daily at 8 h interval for a period of 21 days. Glucokinase and glucose-6-phosphatase activities were respectively determined using standard protocols. Hepatic and muscle glycogen contents were estimated as well. Results STZ caused significant decrease in glucose-6-phosphatase activity and concomitant increase in glucokinase activity. SE extract especially at 400 mg dosage significantly reversed the alterations by increasing glucokinase activity by 40.31% and inhibiting glucose-6-phosphatase activity by 37.29% compared to diabetic control animals. However, the effects were significantly lower than that of METF which enhanced glucokinase activity by 94.76% and simultaneously inhibited glucose-6-phosphatase activity by 49.15%. The extract also improved hepatic glycogen level by 32.37 and 27.06% at 400 and 800 mg dosage respectively. HPLC-MS analysis of some SE fractions in dynamic MRM mode (using the optimized compound-specific parameters) revealed among other active compounds, the presence of amentoflavone, which has been associated with antidiabetic function. Conclusions The ability of SE extract to concurrently inhibit glucose-6-phosphatase and activate glucokinase in this study suggests that it may be a treatment option for type 2 diabetes patients, and the presence of amentoflavone in the plant extract may account for its anti-diabetic potential.
ABSTRACT
Objective: To examine the effects of Sapium ellipticum (SE) leaf extract on the hepatic activities of glucokinase and glucose-6-phosphatase in streptozotocin-induced diabetic Wistar rats. Methods: STZ-induced diabetic Wistar rats (four groups, n=8) were used in this study. SE was assessed at two different doses, 400 and 800 mg/kg BW, in comparison with metformin (METF) (12 mg/kg BW) as a reference antidiabetic drug. All treatments were done orally (p.o), twice daily at 8 h interval for a period of 21 days. Glucokinase and glucose-6-phosphatase activities were respectively determined using standard protocols. Hepatic and muscle glycogen contents were estimated as well. Results: STZ caused significant decrease in glucose-6-phosphatase activity and concomi-tant increase in glucokinase activity. SE extract especially at 400 mg dosage significantly reversed the alterations by increasing glucokinase activity by 40.31%and inhibiting glucose-6-phosphatase activity by 37.29%compared to diabetic control animals. However, the ef-fects were significantly lower than that of METF which enhanced glucokinase activity by 94.76%and simultaneously inhibited glucose-6-phosphatase activity by 49.15%. The extract also improved hepatic glycogen level by 32.37 and 27.06% at 400 and 800 mg dosage respectively. HPLC-MS analysis of some SE fractions in dynamic MRM mode (using the optimized compound-specific parameters) revealed among other active compounds, the presence of amentoflavone, which has been associated with antidiabetic function. Conclusions: The ability of SE extract to concurrently inhibit glucose-6-phosphatase and activate glucokinase in this study suggests that it may be a treatment option for type 2 diabetes patients, and the presence of amentoflavone in the plant extract may account for its anti-diabetic potential.
ABSTRACT
ObjectiveTo study the effect of high altitude (HA) of 4300 m on the hepatic gluconeogenesis in rats and its underlying mechanism. MethodsThirty-six healthy adult male Sprague-Dawley (SD) rats were randomly assigned to group H1 (HA exposure for 1 day, n=6), group H3 (HA exposure for 3 days, n=6), group H7 (HA exposure for 7 days, n=6), group H15 (HA exposure for 15 days, n=6), group H30 (HA exposure for 30 days, n=6), and group C (no HA exposure, n=6). After the treatment, the mRNA and protein levels of glucose-6-phosphatase (G6Pase), and forkhead box transcription factor O1 (FoxO1) in the hepatic tissues were determined by RT-PCR and Western blot, respectively. The content of hepatic glycogen was determined by spectrophotometry, and the blood glucose level was measured using an automatic biochemical analyzer. The one-way analysis of variance (ANOVA) was used to analyze the differences between groups, and the Tukey test was further used to compare the differences between two groups. ResultsCompared with those in group C, the levels of G6Pase and glycogen in the hepatic tissues of rats increased significantly in groups H1, H3, and H7 (P＜0.05), and the expression level of FoxO1 decreased significantly in groups H3, H7, H15, and H30 (P＜0.01). No significant differences in the concentration of blood glucose were observed between the HA-treated groups. ConclusionIncreased hepatic gluconeogenesis and glycogen synthesis in the early phase of HA exposure may be one of the important mechanisms of HA acclimatization. FoxO1 and AMPK are involved in the regulation of hepatic gluconeogenesis. The increased content of hepatic glycogen is associated with the decreased activity of AMPK.
ABSTRACT
Objective To explore the effect of oleanic acid on key enzyme activity in insulin-resistant HepG2 cells. Methods The HepG2 cells were divided into normal control,model control,metformin,and oleanic acid groups.Glycogen content in insulin-resistant HepG2 cell model were detected by hepatic glycogen test kit upon treatment with oleanic acid.Activities of glucokinase ( GK) ,phosphoenolpyruvate carboxylase kinase (PEPCK),and glucose-6-phosphatase (G-6-Pase) were assayed by the glucose 6-phosphate dehydrogenase coupling colorimetric, lactate dehydrogenase coupling colorimetric and ammonium molybdate constant phosphorus methods. Results The oleanic acid enhanced glucose consumption,lowered the activity of G-6-Pase and PEPCK by 54.8% and 18.8%,respectively,and increased the activity of GK and glycogen content in also insulin-resistant HepG2 cells by 100.6% and 98.6%,respectively. Conclusion Aqueous extracts of shirako play a role in lowering PEPCK and G-6-Pase activities and inhibiting glucogenesis, resulting in the reduction of endogenous glucose in the cell. In addition,it can augment the activity of GK,accelerate the process of glucolysis,increase the glycogen content,and alleviate insulin resistance of HepG2.
ABSTRACT
La enfermedad de von Gierke, también conocida como enfermedad de deposito de glucógeno tipo Ia, es una enfermedad producida por la deficiencia de la unidad catalítica de la G6Pasa-a, encargada de hidrolizar la glucosa 6 fosfato en el citoplasma celular durante la gluconeogénesis y la glucogenolisis. Las complicaciones a largo plazo son hipoglicemia severa y alteraciones en el crecimiento. En los niños más pequeños la enfermedad típicamente se presenta con crisis convulsivas y hepatomegalia que se manifiestan a los 6 y 8 meses. Otras complicaciones son osteoporosis, gota, enfermedad renal, hipertensión pulmonar y adenomas hepáticos que pueden malignizarse. No se ha encontrado una cura y de no recibir un manejo adecuado es letal en las primeras dos décadas de la vida. El tratamiento consiste en terapia nutricional, asociada a varios medicamentos convencionales. Algunos pacientes pueden requerir transplante renal o transplante hepático. Una nueva esperanza se ha abierto con el advenimiento de la terapia génica con vectores virales, esta estrategia hasta ahora esta siendo desarrollada, pero los estudios realizados han mostrado una luz de esperanza para investigadores, médicos y pacientes. Faltan estudios para que estos tratamientos permitan un beneficio a largo plazo y su aplicación en humanos, ya que las pruebas como es de esperarse solo han sido desarrolladas en modelos animales.
Von Gierke disease, also known as glycogen storage disease type Ia, is a disease caused by deficiency of the G6Pase-a catalytic unit, which hydrolyzes glucose-6- phosphate in the cell cytoplasm during gluconeogenesis and glycogenolysis. Long term complications include severe hypoglycemia and growth disturbances. In small children, the disease typically presents with seizure crisis and hepatomegaly which become manifest at the age of 6 and 8 months. Other complications include osteoporosis, gout, renal disease, pulmonary hypertension and hepatic adenomas which can become malignant. No cure has been found for this disease and it can turn out to be lethal if no appropriate management is given during the first two decades of life. The treatment consists of nutritional therapy associated with a number of conventional drugs. Some patients may require renal or liver transplant. A new hope has emerged with the arrival of gene therapy with viral vectors, strategy that is being developed hitherto, yet performed studies have shown a glimmer of hope for investigators, doctors and patients. There is a need for studies so these treatments allow for a longer term benefit and their application in humans since, as expected, the tests have been developed only in animal models.
A doença de Von Gierke, também conhecida como Glicogenose tipo I, é uma doença produzida pela deficiência da unidade catalítica da G6Pasa-a, encarregada de hidrolisar a glicose 6 fosfato no citoplasma celular durante a gliconeogênese e a glicogenólise. As complicações a longo prazo são hipoglicemia severa e alterações no crescimento. Nas crianças menores a doença se apresenta tipicamente com crises convulsivas e hepatomegalia que se manifestam aos 6 e 8 meses. Outras complicações são osteoporose, gota, doença renal, hipertensão pulmonar e adenomas hepáticos que podem malignizar-se. Não foi encontrada uma cura e se não recebe tratamento adequado é letal nas primeiras duas décadas de vida. O tratamento consiste em terapia nutricional, associada a vários medicamentos convencionais. Alguns pacientes podem requerer transplante renal ou transplante hepático. Uma nova esperança apareceu com a terapia gênica com vetores virais, esta estratégia até agora esta sendo desenvolvida, mas os estudos realizados mostram uma luz de esperança para pesquisadores, médicos e pacientes. Faltam estudos para que estes tratamentos permitam um beneficio a longo prazo e a sua aplicação em humanos, já que os testes como é de se esperar só foram desenvolvidos em modelos animais.
Subject(s)
Humans , Child , Glycogen Storage Disease Type I , Genetic Therapy , Carcinoma, Hepatocellular , GlycogenABSTRACT
From the cholroform extract of the aerial parts of Couepia paraensis the triterpenes beta-sitosterol1, betulinic acid acetate 2, and oleanolic acid acetate 3, were isolated. Six triterpenes from the chloroform-methanol, acids: oleanolic 4, pomolic 5, ursolic 6, betulinic 7, 6-beta-hydroxybetulínic 8. Additionally from the methanolic extract three flavonoids were isolated: mricetin 9, quercetin 10 y rutina 11. The chloroform and chloroform-methanol extracts were not citotoxic at concentration of 2,5 and 3,1 ug/ml respectively after 24 hours of incubation. The methanol extract was found to be harmless to a concentration of 50 ug/ml, both at 24 hours (LD50 = 10.77 ug/ml) and 120 hours (LD50 = 28.86 ug/ml) of incubation. Only the methanol extract showed significant inhibition (41 percent) of the activity of G-6-Pase in intact microsomes without affecting the activity of the enzyme in microsomes broken.
Se aislaron e identificaron tres triterpenos: beta-sitosterol 1, acetato del ácido betulínico, 2 y acetato del ácido oleanólico 3 del extracto clorofórmico. Seis triterpenos del extracto cloroformo: metanol (9:1) que fueron identificados como ácidos: oleanólico 4, pomólico 5, ursólico 6, betulínico 7, 6-beta-hidroxibetulínico 8. Mientras que del extracto metanólico se identificaron 3 flavoniodes: miricetina 9, quercetina 10 y rutina 11. Los extractos de cloroformo y cloroformo /metanol resultaron inocuos hasta las concentraciones de 2,5 y 3,1ug/ml respectivamente, después de 24 horas de incubación. El extracto metanólico es inocuo hasta una concentración de 50 ug/ml, tanto a 24 horas (LD50 = 10,77 ug/ml) como a 120 horas (LD50 = 28,86 ug/ml) de incubación. Solamente el extracto metanólico mostró una inhibición significativa (41 por ciento) de la actividad de la G-6-Pasa de microsomas intactos sin afectar la actividad de la enzima en microsomas rotos.
Subject(s)
Cytotoxins , Chrysobalanaceae/chemistry , Flavonoids/analysis , /antagonists & inhibitors , Triterpenes/analysis , Time FactorsABSTRACT
Monosodium glutamate (MSG) is a widely used flavour enhancer with a number of adverse effects. Earlier studies have shown the induction of oxidative stress in some organs of experimental animals after chronic administration of MSG. Some reports have also shown some alterations in hepatic glucose metabolism as a result of MSG administration. In this study, we have tested the hypothesis that alteration in glucose metabolism following MSG administration might be a contributor to the changes in the markers of oxidative stress observed in the animals. Twenty four male Wistar rats were divided into two groups. MSG was orally administered to one group of rats at a dose of 4g/kg body weight for ten days while the other group received normal saline. MSG-treated rats showed a significant alteration (P<0.05) in a number of oxidative stress parameters and a significant (P<0.05) increase in the activity of glucose-6- Phosphatase (G6Pase), corroborating earlier observations. In addition, there was a decrease in the activity of glucose-6-phosphate dehydrogenase (G6PD) and a significantly (P<0.05) higher blood glucose and renal glucose concentration in MSG-treated rats. There was no change in renal glycogen concentration following MSG administration. The pattern of induction of oxidative stress and alteration of glucose metabolic enzymes in the animals is an indication that oxidative stress induced by MSG in the renal tissues of rats might be contributed by increased tissue glucose concentration resulting from enhanced renal gluconeogenesis.
ABSTRACT
Objective To observe the perioperative management of cardiac surgery and extracorporeal circulation method in patients with glucose-6-phosphate dehydrogenase deficiency(G6PD).Methods Ten patients with G6PD deficiency underwent uneventful cardiac surgery procedures between January 2005 and December 2010.Twenty patients who had non-G6PD deficiency were as a control group,the selected conditions were the same gender,age,body mass,the risk of heart disease surgery.The preoperative management in patients with G6PD deficiency mainly focused on avoiding the drugs implicated in haemolysis,reducing the surgical stress,using moderate hypothermia extracorporeal circulation and enhancing blood conservation.Observed indicators included the assisted ventilation time,urine volume,the drainage volume of chest tube,the amount transfusion of red blood cells and plasma,the level of hemoglobin and serum total bilirubin in the 2nd day after surgery,ICU stay.Results Compared with the control group,patients with G6PD deficiency had no significant difference in duration of ventilation after the operation,drainage,urine,Hgb,bilirubin levels,and blood transfusion[(9.3 ± 4.5)h vs (8.6 ± 5.7)h,(2100 ±670)ml vs (1950 ± 490) ml,(253 ± 146)ml vs (260 ± 120)ml,(1.3 ± 1.0)U vs (1.8 ± 1.2)U,(96 ± 25)g/L vs (99 ± 12)g/L,and (24 ± 8)μmol/L vs (27 ± 1 l)μmol/L,t =0.978,2.032,1.257,0.891,2.182,2.271,and 1.329,all P ＞ 0.05].The duration of ICU discharge was significantly longer in the glucose-6-phosphate dehydrogenase deficient group[ (2.6 ± 0.6)d vs (1.8 ± 1.5)d,t =2.704,P ＜ 0.05].Conclusions Cardiac surgery can be performed safely in patients with G6PD deficiency with enhanced perioperative management.
ABSTRACT
Os extratos aquoso e etanólico derivados de doze espécies coletadas na Amazônia venezuelana foram testados quanto à atividade antioxidante utilizando um radical DPPH e o efeito inibitório sobre a hidrólise de glicose-6-fosfato nos microssomas intactos e perturbados. Sem exceção, todos os extratos inibiram, em maior ou menor grau, a atividade enzimática microssomal de G-6-Pase, resultando em maior inibição nos microssomas intactos do que nos perturbados. Efeitos marcantes foram observados para os extratos aquoso e etanólico de: Tontelea ovalifolia, Gustavia pulchra, Phthirusa verruculosa, Phthirusa castillana, Psittacanthus acimarius, Tetrapterys styloptyera e Vismia japurensis. Os extratos etanólicos foram seqüestradores do radical DPPH mais eficazes do que os correspondentes extratos aquosos em todos os casos. O extrato etanólico de Endlicheria anomala e o extrato aquoso de Phthirusa verruculosa exibiram as melhores CI50 com 100 e 250.0 ppm, respectivamente. Os valores de Kobs calculados para os extratos alcoólicos foram mais baixos do que os dos extratos aquosos das mesmas espécies, exceto Psittacanthus acimarius. Estes resultados poderiam estar relacionados a diferentes concentrações, ou mais provavelmente a diferentes composições de princípios ativos em ambos extratos.
The aqueous and ethanol extracts derived from twelve plant species collected in the Venezuelan Amazon have been tested for antioxidant activity using a DPPH radical and inhibitory effect on the hydrolysis of glucose-6-phosphate in intact and disrupted microsomes. Without exception, all the extracts inhibited, to a greater or lesser degree, microsomal G-6-Pase enzymatic activity, resulting in greater inhibition on intact microsomes than on disrupted ones. Marked effects were observed for aqueous and ethanol extracts of: Tontelea ovalifolia, Gustavia pulchra, Phthirusa verruculosa, Phthirusa castillana, Psittacanthus acimarius, Tetrapterys styloptyera and Vismia japurensis. Ethanol extracts were more effective DPPH radical scavengers than the corresponding aqueous extracts in all the cases. The ethanol extract of Endlicheria anomala and the aqueous extract of Phthirusa verruculosa, showed the best IC50 with 100 and 250.0 ppm, respectively. The Kobs calculated for the alcoholic extracts were lower than those of the aqueous extracts for the same species, except Psittacanthus acimarius. These results could be related to different concentrations, or more likely different compositions of active principles in both extracts.
ABSTRACT
This study investigated the therapeutic effects of Inonotus obliqua extract on blood glucose, insulin, and other biochemical parameters in genetically diabetic mice (C57BL/KsJ-m+/+Lepr(db)). The mice were divided into four groups - control, Chaga 1 (dose of 0.09 mg/kg of body weight), Chaga 5 (5 times of Chaga 1), and Chaga 10 (10 times of Chaga 1)- according to supplemented dose. Inonotus obliqua extract was orally administered to the animals for 6 weeks. The body and organ (liver and kidney) weights were not different among groups. Fasting blood glucose level was significantly lower in the Chaga 5 group compared with the control (p < 0.05). Hemoglobin A1c content was significantly lower in the Chaga 5 group compared with either the control and Chaga 1 group (p < 0.05). There was no significant difference in serum insulin level among groups. The glucose-6-phosphatase activity in liver was significantly the lowest in Chaga 10 group and was significantly lower in Chaga 5 group as compared with those of control and Chaga 1 groups. Therefore, the results of this study demonstrate that Inonotus obliqua extract alleviates many of the symptoms of diabetes in genetically obese mice and may offer a possibility as a therapeutic supplement for the normalization of blood glucose levels in human with hyperglycemia and have beneficial effects in patients with noninsulin-dependent diabetes mellitus.
Subject(s)
Animals , Humans , Mice , Blood Glucose , Diabetes Mellitus, Type 2 , Fasting , Glucose-6-Phosphatase , Hyperglycemia , Insulin , Liver , Mice, Obese , Weights and MeasuresABSTRACT
PURPOSE: Glycogen storage disease type Ia (GSD Ia) is an autosomal recessive disease characterized by hepatosplenomegaly, short stature, hypoglycemia, hyperuricemia and lactic academia. It is caused by mutations of glucose-6-phosphatase (G6Pase) gene located on chromosome 17q21. The study were undertaken to investigate clinical manifestations and genotype as well as to evaluate the effects of uncooked corn starch (UCCS) on height growth of pubertal and prepubertal subjects with GSD Ia. METHODS: We analyzed clinical data from 24 GSD Ia patients retrospectively by medical record review. Height standard deviation score (Ht-SDS) was calculated from 13 GSD Ia patients under age 15 treated with UCCS and followed-up over 1 year. DNA isolation, PCR reaction and DNA sequencing analysis were performed in all studied patients. RESULTS: Hypertriglyceridemia (100%), elevated liver enzyme (85%), hyperuricemia (48%), hypercholesterolemia (45%), anemia (45%) were major laboratory findings in studied population. Four different mutations of G6Pase gene in 48 alleles were identified. C.648G>T mutation was the predominant mutation, allele frequency of which was 78.6% (33 alleles). The other mutations were p.Phe51Ser, p.Gly222Arg, p.Gly122Asp. The p.Phe51Ser was a novel mutation. Mean Ht-SDS at diagnosis and two years after UCCS treatment were -2.04+/-1.69 and -0.72+/-1.12 respectively, which were statistically significant (P=0.036). CONCLUSION: The genotype of the G6Pase gene was nearly homogeneous in Korean patients with GSD Ia. Molecular analysis of the G6Pase gene will be the diagnosis of choice since the c.648G>T mutation accounts for 78.6% of mutations in Korean patients with GSD Ia. UCCS treatment has a beneficial effect on height growth of children and adolescents with GSD Ia.
Subject(s)
Adolescent , Child , Humans , Alleles , Anemia , Diagnosis , DNA , Gene Frequency , Genotype , Glucose-6-Phosphatase , Glycogen Storage Disease , Glycogen , Hypercholesterolemia , Hypertriglyceridemia , Hyperuricemia , Hypoglycemia , Liver , Medical Records , Polymerase Chain Reaction , Retrospective Studies , Sequence Analysis, DNA , Starch , Zea maysABSTRACT
The effect(s) of two doses of Light Crude Oil (LCO) on the concentrations of regenerative DNA, total protein and glucose-6-phosphatase activity, as molecular indices of potential carcinogenicity was determined in liver homogenates of partially-hepatectomized and non-hepatectomized (normal) rat liver. Rats were treated with intraperitoneal injection at six hours, and sacrificed twenty-four hours post-partial hepatectomy (pph); control rats were partially hepatectomized but not treated; while reference rats (with normal liver) were non-hepatectomized and not treated. Regenerative DNA was partially purified from liver homogenates and quantified by the diphenylamine method; total protein concentration was determined directly in the homogenates by the Biuret method; and glucose-6-phosphatase activity by a modification of the Fiske-Subbarow method. Results showed a 21.5% increase in glucose-6-phosphatase activity in partially-hepatectomized rat liver over non-hepatectomized controls, 59.3% and 9.8% increases in total homogenate protein concentration at 2.5 and 5.0ml/kg body weight (bw) LCO respectively; 68.2% and 46.0% increases in glucose-6-phosphatase activity at 2.5 and 5.0 ml/kg bw over the control, respectively. Increases in partially-purified regenerative DNA concentrations also occurred at 13.7% and 20.5% over the controls at 2.5 and 5.0 ml/kg bw, respectively. Nigerian light crude oil (LCO) apparently induced increases in both regenerative DNA and protein syntheses at the first wave of synthesis (24hrs. pph) at the two dose levels tested, while also inducing increases in the bio-transformation by, or perhaps synthesis of, microsomes (cytochrome P450 and 448 detoxification enzymes) as judged by the increased level of the marker enzyme glucose-6-phosphatase. These results may shed more light on the probable molecular mechanism of LCO's potential carcinogenicity and/or toxicity.
ABSTRACT
PURPOSE: Glycogen storage disease type Ia (GSD Ia) is an autosomal recessive disorder caused by the deficiency of glucose-6-phosphatase (G6Pase). The aim of the study was to investigate the spectrum of G6Pase gene mutations and relationship between genotype and clinical findings in Korean patients with GSD Ia. METHODS: Genomic DNA was extracted from peripheral leukocytes of 20 patients with GSD Ia. The five exons of G6Pase gene were amplified and PCR products were directly sequenced. The frequency of short stature, hypoglycemia, hypercholesterolemia, hyperuricemia, hypercalciuria, nephrocalcinosis and hepatic adenoma was compared between 727G> T homozygotes and 727G> T compound heterozygotes. RESULTS: A total of 5 different mutations were identified. The most common mutation was the 727G> T with an allele frequency of 80%. All patients were either homozygous (12/20) or heterozygous (8/20) for the 727G> T mutation. G122D was found in 3 patients, P178A in 1, G222R in 2, and S339R in 2. There was no difference in the frequency of short stature, hypoglycemia, hypercholesterolemia, hyperuricemia, nephrocalcinosis, and hepatic adenoma between 727G> T homozygotes and heterozygotes. CONCLUSION: Diagnosis of GSD Ia can be based on clinical and biochemical abnormalities combined with mutation analysis instead of enzymatic diagnosis that requires liver biopsy. Homozygosity for the 727G> T does not seem to alter the disease phenotype as compared with the heterozygous state.
Subject(s)
Humans , Adenoma , Biopsy , Diagnosis , DNA , Exons , Gene Frequency , Genotype , Glucose-6-Phosphatase , Glycogen Storage Disease , Glycogen , Heterozygote , Homozygote , Hypercalciuria , Hypercholesterolemia , Hyperuricemia , Hypoglycemia , Leukocytes , Liver , Nephrocalcinosis , Phenotype , Polymerase Chain ReactionABSTRACT
Glycogen storage disease type Ia (GSD-Ia) is an autosomal recessive disorder that has defects in glucose-6-phosphatase (G6Pase) in liver, kidney and intestinal mucosa. The defect leads to inadequate conversion of glucose-6-phospate to glucose in the liver and thus makes affected individuals susceptible to fasting hypoglycemia, hyperuricemia, lactic acidemia and hyperlipidemia. Hyperuricemia has been observed in a considerable number of patients and in some of those, clinical gout has occurred. Inhibited tubular secretion of uric acid due to hyperlacticacidemia and ketonemia, and overproduction of uric acid have been postulated as a mechanism for hyperuricemia in patients with GSD-Ia. A 30-year-old male was admitted with fatigue, foot pain and multiple gouty tophi on knee, ankle, and elbow. GSD-Ia and gout were confirmed by analysis of the G6Pase gene and tophi aspiration respectively. He was treated with allopurinol and uncooked cornstarch. After treatment, foot pain improved and the number and size of tophi were decreased.
Subject(s)
Adult , Humans , Male , Allopurinol , Ankle , Elbow , Fatigue , Foot , Glucose , Glucose-6-Phosphatase , Glycogen Storage Disease , Glycogen , Gout , Hyperlipidemias , Hyperuricemia , Hypoglycemia , Intestinal Mucosa , Ketosis , Kidney , Knee , Liver , Starch , Uric AcidABSTRACT
PURPOSE: Glycogen storage disease type Ia (GSD Ia) is an autosomal recessive disorder of glycogen metabolism caused by glucose-6-phosphatase (G6Pase) deficiency. The clinical manifestations of G6Pase deficiency include growth retardation, hepatomegaly, hypoglycemia, lactic acidemia, hyperlipidemia and hyperuricemia. Many mutations of this gene have been found worldwide in various ethnic groups, establishing the molecular basis of GSD Ia. To elucidate a spectrum of the G6Pase gene mutations in Korean, we analyzed mutations in Korean patients with GSD Ia. METHODS: Both alleles of 9 unrelated GSD 1a patients were studied by PCR and direct DNA sequencing methods. In all patients, GSD 1a was diagnosed by the enzyme assay for the liver biopsy specimen. RESULTS: In Korean, the most prevalent mutation was g727t substitution in exon 5, which has been reported to cause abnormal mRNA splicing: Sixteen out of 18 alleles were found to have this mutation. In addition, we identified one novel mutation, a c611g, converting a proline to an alanine at codon 178. CONCLUSION: Our findings suggest that a screening for the g727t mutation by noninvasive molecular method can detect most cases of GSD Ia in Korean patients.
Subject(s)
Humans , Alanine , Alleles , Biopsy , Codon , Enzyme Assays , Ethnicity , Exons , Glucose-6-Phosphatase , Glycogen Storage Disease , Glycogen , Hepatomegaly , Hyperlipidemias , Hyperuricemia , Hypoglycemia , Liver , Mass Screening , Metabolism , Polymerase Chain Reaction , Proline , RNA, Messenger , Sequence Analysis, DNAABSTRACT
Six-week-old Sprague Dawley rats were fed the diets of 20% casein or soy protein. Two weeks after the feeding, hepatocellular chemical carcinogenesis was initiated by diethylnitrosamine(DEN), and promoted by the diet containing 0.01% 2-acetylamino-fluorene(AAF) and two-thirds partial hepatectomy(PH). The animals were sacrificed at 8 weeks after the DEN injection. The area of placetal glutathione S-trnasferase(GST-P) positive foci, the activities of several enzymes in cellualr antioxidant enzyme systems and glucose 6-phosphatase were determined to investigate the mechanism of the anticarcinogenic effect by the dietary proteins. In another set of experiments, the drinking water of rats fed casein was supplemented with 1.5% inositol hexaphosphate(InsP6) to elucidate whether it has the comparable anticancer action of soy protein. The area and number of GST-P positive foci in the soy protein group were significantly(p<0.05) lower than those inthe casein group. The livers of rats fed casein showed moderate fattydegeneration and larger hyperplastic nodules than those of rats fed soy protein. In another set of experiments, the area and number of GST-P positive foci in the rats fed casein supplemented with InsP6 were not significantly different from those in the rats fed casein or soy protein. The lipid peroxidation of rats fed different protein sources showed no significant difference. Glutathione S-transferase(GST) activities were increased significantly(p<0.05) by carcinogen treatment in all dietary groups. Glucose 6-phosphatase(G6Pase) activities were decreased by carcinogen treatment, and hence showed a reverse relationship(r=-0.695, p<0.01) to the GST-P positive foci. Therefore, the activities in the rats fed casein were lower than those in the rats fed soy protein. These results suggest that the soy protein seems to be more anti-carcinogenic than casein by decreasing the preneoplastic lesion and by increasing the membrane stability but inositol hexaphosphate, a component of soy protein, may not be protective against hepatocarcinogenesis.